The neurocytokine, interleukin-6, corrects nerve dysfunction in experimental diabetes

Experimental Neurology

Volumn 207, Issue 1, 2007, Pages 23-29

  Cameron, Norman E ^a   Cotter, Mary A ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Allodynia; Blood flow; Diabetes; Interleukin 6; Nerve conduction; Neuropathy; Pain

Indexed keywords

INTERLEUKIN 6; STREPTOZOCIN;

ACUTE PHASE RESPONSE; ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; EXPERIMENTAL DIABETES MELLITUS; HEMATOPOIESIS; HYPERALGESIA; IMMUNE RESPONSE; IMMUNOREGULATION; MALE; NERVE CONDUCTION; NERVE GROWTH; NEUROPATHY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMORAL NERVE; HYPERALGESIA; INTERLEUKIN-6; MALE; NEURAL CONDUCTION; NEURONS, AFFERENT; PERIPHERAL NERVES; RATS; RATS, SPRAGUE-DAWLEY; REGIONAL BLOOD FLOW; SCIATIC NERVE;

EID: 34548331598     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2007.05.009     Document Type: Article

References (48)

1. Akaneya Y., Takahashi M., and Hatanaka H. Interleukin-1 beta enhances survival and interleukin-6 protects against MPP+ neurotoxicity in cultures of fetal rat dopaminergic neurons. Exp. Neurol. 136 (1995) 44-52
2. Andriambeloson E., Baillet C., Vitte P.-A., Garotta G., Dreano M., and Callizot N. Interleukin-6 attenuates the development of experimental diabetes-related neuropathy. Neuropathology 26 (2006) 32-42
3. Bianchi M., Maggi R., Pimpinelli F., Rubio T., Parolaro D., Poli V., Cilberto G., Panerari A.E., and Sacerdote P. Presence of a reduced opioid response in interleukin-6 knock out mice. Eur. J. Neurosci. 11 (1999) 1501-1507
4. Calcutt N.A., Muir D., Powell H.C., and Mizisin A.P. Reduced ciliary neuronotrophic factor-like activity in nerves from diabetic or galactose-fed rats. Brain Res. 575 (1992) 320-324
5. Calcutt N.A., Freshwater J.D., and Mizisin A.P. Prevention of sensory disorders in diabetic rats by aldose reductase inhibition or threatment with ciliary neurotrophic factor. Diabetologia 47 (2004) 718-724
6. 2 antagonists on neurovascular function in diabetic rats. Naunyn-Schmeideberg's Arch. Pharmacol. 367 (2003) 607-614
7. Cameron N.E., Cotter M.A., and Robertson S. The effect of aldose reductase inhibition on the pattern of nerve conduction deficits in diabetic rats. Q. J. Exp. Physiol. 74 (1989) 917-926
8. Cameron N.E., Cotter M.A., and Low P.A. Nerve blood flow in early experimental diabetes in rats: relation to conduction deficits. Am. J. Physiol. 261 (1991) E1-E8
9. Cameron N.E., Cotter M.A., Dines K.C., Maxfield E.K., Carey F., and Mirrlees D. Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: dose-response considerations and independence from a myo-inositol mechanism. Diabetologia 37 (1994) 651-663
10. Cameron N.E., Eaton S.E.M., Cotter M.A., and Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 44 (2001) 1973-1988
11. Cameron N.E., Jack A.M., and Cotter M.A. Effect of α-lipoic acid on vascular responses and nociception in diabetic rats. Free Radic. Biol. Med. 31 (2001) 125-135
12. Cameron N.E., Tuck Z., McCabe L., and Cotter M.A. Effects of the hydroxyl radical scavenger, dimethylthiourea, on peripheral nerve tissue perfusion and function in experimental diabetes. Diabetologia 44 (2001) 1161-1169
13. Carey A.L., and Febbraio M.A. Interleukin-6 and insulin sensitivity: friend or foe?. Diabetologia 47 (2004) 1135-1142
14. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., and Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J. Neurosci. Methods 53 (1994) 55-63
15. Choi H.S., Ju J.S., Lee H.J., Kim B.C., Park J.S., and Ahn D.K. Effects of intracisternal injection of interleukin-6 on nociceptive jaw opening reflex and orofacial formalin test in freely moving rats. Brain Res. Bull. 59 (2003) 365-370
16. Coppey L.J., Gellett J.S., and Yorek M.A. Mediation of vascular relaxation in epineurial arterioles of the sciatic nerve: effects of diabetes in type 1 and type 2 diabetic models. Endothelium 10 (2003) 89-94
17. 1 adrenoceptor antagonist treatment: interactions with the nitric oxide system. Eur. J. Pharmacol. 343 (1998) 217-223
18. Cotter M.A., Jack A.M., and Cameron N.E. Effects of the protein kinase C β-isoform inhibitor, LY333531, on neural and vascular function in streptozotocin-diabetic rats. Clin. Sci. 103 (2002) 311-321
19. 2 clearance curves used to measure blood flow in rat sciatic nerve. J. Physiol. 414 (1989) 35-54
20. Dixon A., Wells C.C., Singh S., Babayan R., and Maric C. Renoprotective effects of a selective estrogen receptor modulator, raloxifene, in an animal model of diabetic nephropathy. Am. J. Nephrol. 27 (2007) 120-128
21. Flatters S.J., Fox A.J., and Dickenson A.H. Spinal interleukin-6 (IL-6) inhibits nociceptive transmission following neuropathy. Brain Res. 984 (2003) 54-62
22. Gadient R.A., and Otten U.H. Interleukin-6 (IL-6)-a molecule with both beneficial and destructive potentials. Prog. Neurobiol. 52 (1997) 379-390
23. Genesca J., Gonzalez A., Segura R., Catalan R., Marti R., Varela E., Cadelina G., Martinez M., Lopez-Talavera J.C., Esteban R., Groszmann R.J., and Guardia J. Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis. Am. J. Gasteroenterol. 94 (1999) 169-177
24. Hama T., Miyamoto M., Tsukui H., Nishio C., and Hatanaka H. Interleukin-6 as a neurotrophic factor for promoting the survival of cultured basal forebrain cholinergic neurons from postnatal rats. Neurosci. Lett. 104 (1989) 340-344
25. Hargreaves K., Dubner R., Brown F., Flores C., and Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32 (1988) 77-88
26. Hirota H., Kiyama H., Kishimoto T., and Taga T. Accelerated nerve regeneration in mice by upregulated expression of interleukin (IL) 6 and IL-6 receptor after trauma. J. Exp. Med. 183 (1996) 2627-2634
27. +ATPase, and glutathione in diabetic rats. Eur. J. Pharmacol. 397 (2000) 335-341
28. Ikeda K., Iwasaki Y., Shiojima T., and Kinoshita M. Neuroprotective effect of various cytokines on developing spinal motoneurons following axotomy. J. Neurol. Sci. 135 (1996) 109-113
29. Jarvis M.F., Wessale J.L., Zhu C.Z., Lynch J.J., Dayton B.D., Calzadilla S.V., Padley R.J., Opgenorth T.J., and Kowaluk E.A. ABT-627, an endothelin ET(A) receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain. Eur. J. Pharmacol. 388 (2000) 29-35
30. Kimura K., Tsuda K., Moriwaki C., Kawabe T., Hamada M., Obana M., Baba A., Hano T., and Nishio I. Leukemia inhibitory factor relaxes arteries through endothelium-dependent mechanism. Biochem. Biophys. Res. Commun. 294 (2002) 359-362
31. Lee J.H., and McCarty R.C. Glycemic control of pain threshold in diabetic and control rats. Physiol. Behav. 47 (1990) 225-230
32. Matsuda S., Wen T.C., Morita F., Otsuka H., Igase K., Yoshimura H., and Sakanaka M. Interleukin-6 prevents ischemia-induced learning disability and neuronal and synaptic loss in gerbils. Neurosci. Lett. 204 (1996) 109-112
33. Minghini A., Britt L.D., and Hill M.A. Interleukin-1 and interleukin-6 mediated skeletal muscle arteriolar vasodilation: in vitro versus in vivo studies. Shock 9 (1998) 210-215
34. Oka T., Oka K., Hosoi M., and Hori T. Intracerebroventricular injection of interleukin-6 induces thermal hyperalgesia in rats. Brain Res. 692 (1995) 123-128
35. Pedersen B.K., Steensberg A., Fischer C., Keller C., Keller P., Plomgaard P., Wolsk-Petersen E., and Febbraio M. The metabolic role of IL-6 produced during exercise: is IL-6 an exercise factor?. Proc. Nutr. Soc. 63 (2004) 263-267
36. Randall L.O., and Sellito J.J. A method for measurement of analgesic activity on inflamed tissue. Arch. Int. Pharmacodyn. Ther. 111 (1957) 409-419
37. Rodriguez M., Pavelko K.D., McKinney C.W., and Leibowitz J.L. Recombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis. J. Immunol. 153 (1994) 3811-3821
38. Shuto T., Horie H., Hikawa N., Sango K., Tokashiki A., Yamamoto I., and Ishikawa Y. IL-6 up-regulates CNTF mRNA and enhances neurite regeneration. NeuroReport 12 (2001) 1081-1085
39. Sjoholm A., and Nystrom T. Inflammation and the etiology of type 2 diabetes. Diabetes Metab. Res. Rev. 22 (2006) 4-10
40. Skundric D.S., and Lisak R.P. Role of neuropoietic cytokines in development and progression of diabetic polyneuropathy: from glucose metabolism to neurodegeneration. Exp. Diabesity Res. 4 (2003) 303-312
41. Streit W.J., Semple_rowland S.L., Hurley S.D., Miller R.C., Popovich P.G., and Stokes B.T. Cytokine mRNA profiles in contused spinal cord and axotomized facial nucleus suggest a beneficial role for inflammation and gliosis. Exp. Neurol. 152 (1998) 74-87
42. Taga T., and Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 15 (1997) 797-819
43. Ugochukwu N.H., and Figgers C.L. Caloric restriction inhibits up-regulation of inflammatory cytokines and TNF-alpha, and activates IL-10 and haptoglobin in the plasma of streptozotocin-induced diabetic rats. J. Nutr. Biochem. 18 (2007) 120-126
44. Vila E., and Salaices M. Cytokines and vascular reactivity in resistance arteries. Am. J. Physiol. 288 (2005) H1016-H1021
45. Wallenius V., Wallenius K., Ahren B., Rudling M., Carlsten H., Dickson S.L., Ohlsson C., and Jansson J.O. Interleukin-6-deficient mice develop mature-onset obesity. Nat. Med. 8 (2002) 75-79
46. Xu X.J., Hao J.X., Andell-Jonsson S., Poli V., Bartfai T., and Wiesenfeld-Hallin Z. Nociceptive responses in interleukin-6-deficient mice to peripheral inflammation and peripheral nerve section. Cytokine 9 (1997) 1028-1033
47. Yamada M., and Hatanaka H. Interleukin-6 protects cultured rat hippocampal neurons against glutamate induced cell death. Brain Res. 643 (1994) 173-180
48. Zhong J., Dietzel I.D., Wahle P., Kopf M., and Heumann R. Sensory impairments and delayed regeneration of sensory axons in interleukin-6-deficient mice. J. Neurosci. 19 (1999) 4305-4313